---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-013875"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T11:28:04.328346+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cumberland's ifetroban shows 5.4% cardiac improvement in DMD Phase 2 trial

## Summary
- High-dose ifetroban improved LVEF by 3.3% vs. placebo and 5.4% vs. natural history controls.
- Results from FIGHT DMD trial selected for late-breaking presentation at MDA Clinical & Scientific Conference.
- Ifetroban has FDA Orphan Drug and Rare Pediatric Disease Designations for DMD heart disease.
- End-of-Phase-2 meeting with FDA planned to discuss next steps for development and commercialization.

## SEC filing metadata
- accession: 0001628280-25-013875
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828025013875/0001628280-25-013875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828025013875/cpix-20250319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-013875
- JSON: https://secwatch.observer/filing/0001628280-25-013875.json
- Plain text: https://secwatch.observer/filing/0001628280-25-013875.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.